id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2019-E-5262-0004,FDA,FDA-2019-E-5262,Determination of Regulatory Review Period for Purposes of Patent Extension; Nuzyra Injection (New Drug Application 209817),Notice,Determinations,2023-11-30T05:00:00Z,2023,11,2023-11-30T05:00:00Z,2024-05-29T03:59:59Z,2023-11-30T18:17:29Z,2023-26363,0,0,09000064862c3351